Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.71

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (15081)	1/4/2005 10:22:14 AM
From: Biomaven	Read Replies (1) of 52153

why doing modified taxol trials hasn't been very straightforward from a regulatory perspective. In the case of APPX one issue was that their comparator was Taxol for second-line breast cancer (which is the US label), but current practice in the US is to use Taxol as first line. So they were forced to enroll overseas, mostly Eastern Europe, and also to mix first and second-line US patients. That said, I think their drug works at least as well as Taxol if not better, and has clear tox and ease-of-use advantages over Taxol. So I guess I'd put it at better than a 50:50 shot for approval. Anyone (rkrw?) know what the company is worth aside from Abraxane? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next